Genome wide measurement of DNA copy number changes in neuroblastoma: dissecting amplicons and mapping losses, gains and breakpointsMichels E. · Vandesompele J. · Hoebeeck J. · Menten B. · De Preter K. · Laureys G. · Van Roy N. · Speleman F.
aCenter for Medical Genetics and bDepartment of Pediatric Hematology and Oncology, Ghent University Hospital, Ghent (Belgium)
In the past few years high throughput methods for assessment of DNA copy number alterations have witnessed rapid progress. Both ‘in house’ developed BAC, cDNA, oligonucleotide and commercial arrays are now available and widely applied in the study of the human genome, particularly in the context of disease. Cancer cells are known to exhibit DNA losses, gains and amplifications affecting tumor suppressor genes and proto-oncogenes. Moreover, these patterns of genomic imbalances may be associated with particular tumor types or subtypes and may have prognostic value. Here we summarize recent array CGH findings in neuroblastoma, a pediatric tumor of the sympathetic nervous system. A total of 176 primary tumors and 53 cell lines have been analyzed on different platforms. Through these studies the genomic content and boundaries of deletions, gains and amplifications were characterized with unprecedented accuracy. Furthermore, in conjunction with cytogenetic findings, array CGH allows the mapping of breakpoints of unbalanced translocations at a very high resolution.
Request reprints from Frank Speleman
Center for Medical Genetics
Ghent University Hospital, De Pintelaan 185
BE–9000 Ghent (Belgium)
telephone: +32 9 240 2451; fax: +32 9 240 6549
Manuscript received: 16 February 2006
Accepted in revised form for publication by A. Geurts van Kessel,: 3 May 2006.
Number of Print Pages : 10
Number of Figures : 3, Number of Tables : 2, Number of References : 88
Cytogenetic and Genome Research
Vol. 115, No. 3-4, Year 2006 (Cover Date: November 2006)
Journal Editor: Schmid, M. (Würzburg)
ISSN: 1424–8581 (print), 1424–859X (Online)
For additional information: http://www.karger.com/CGR